Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for license extension of venetoclax (Venclyxto)

CHMP recommended a license extension in combination with obinutuzumab, for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.

European Medicines Agency